A preliminary analysis based on high-resolution metabolomics pointed to three blood plasma metabolites with apparent ties to active, pulmonary tuberculosis.
The tool allows users to search for unexpected modifications and other phenomena that are difficult to identify using conventional mass spec search software.
The scientists developed a metabolomic panel capable of predicting BMI and identifying subsets of at-risk patients with apparently healthy BMIs.
A team from the EPFL has identified the chemical NTCB as a potential digestion reagent for middle-down work, though bioinformatic hurdles still remain.
The group's meeting this week evidenced the ongoing shift towards analyzing proteins in the context of specific isoforms, complexes, and cells.
The agreement is part of a larger effort by the company to apply its Signabody affinity reagents to toxicity biomarker work and other areas of drug development.
Based on multiplexed ion beam imaging, the system, which the company plans to launch next year, will compete most directly with Fluidigm's Hyperion platform.
According to the company, its approach allows for improved detection of EV-bound proteins and phosphoproteins, which it is using for biomarker discovery.
The companies will jointly promote Visiopharm's Phenomap image-analysis software alongside Fluidigm's Hyperion imaging system and related products.
After an unsuccessful commercialization attempt more than a decade ago, the company is bringing a revamped version of the ion mobility technology to market.
According to the researchers, this is one of the first successful such predictions and could aid the understanding of links between gene expression and metabolism.
PNNL researchers have developed a targeted mass spec approach that they said could enable single-cell measurement of the 2,500 most abundant human proteins.
A workflow developed by the company along with Max Planck researchers demonstrates the system's potential for enabling high-throughput proteomic experiments.
The method combines stable isotope dimethyl labeling with DiLeu isobaric tagging and allows multiplexing of up to 24 samples in a single mass spec experiment.
The ability to effectively use FFPE tissue opens up a large number of clinical samples for analysis, many with quality data on patient demographics, treatment, and outcomes.
UCSD plans to expand the Metabolomics Workbench to include a wide range of clinical trials data including demographics and trial protocols.
A group led by St. Jude Children's Research Hospital integrated transcriptomic, epigenomic, proteomic, and phoshoproteomic data.
The mass spec technology company plans to bring three products to market in the next year, including an integrated LC-MEA device and an ion source.
The company said the funds will be used to expand its management team and complete commercialization of its mass spec multinozzle emitter array technology.
The company reported revenues of $443.7 million and organic growth of 3 percent, driven in large part by strength in its scientific instruments business.
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.
New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.
The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.
In Nature this week: protein-coding variants associated with body-fat distribution, and more.